Hematology / Oncology Clinic  

Clinical Trials

The Doctors at the Hematology\Oncology Clinic have more than 20 years of experience in conducting and treating patients on national clinical trials.

Because of their dedication to cancer treatment they are able to offer patients access to the latest treatment options available..

ACTIVE CLINICAL PROTOCOLS

BREAST

Novartis CBYL719C2301 :  (SOLAR-1) A phase III randomized double-blinded, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER-2 negative advanced breast cancer which progressed on or after aromatase inhibitor treatment.   www.clinicaltrials.gov.  NCT02437318

NRG-BR003:  A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node Negative Triple-Negative Invasive Brest Cancer. [PI:  McCanless]
www.clinicaltrials.gov.  NCT02488967

LYMPHOMA

GILEAD-GS-US-339-0102 (PPD): A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmocodynamics of GS-9973 BTK Inhibitor) in Subjects with Relapsed or Refractory Hematologic Malignancies:  (CLL arm only opened). [PI:  Castine].  Closure anticipated end 1st quarter 2016.
www.clinicaltrials.gov.  NCT01799889

ROBUST CELGENE  DL002:  Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
www.clinicaltrials.gov.  NCT02285062

MYELOMA

E3A06:  Randomized Phase II Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma.
www.clinicaltrials.gov.  NCT01169337

REGISTRY

PROCLAIM: 10PLK13: Proleukin® Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy (Renal or Melanoma).
www.clinicaltrials.gov.  NCT01415167

REVEAL-INCYTE MA-PV-401: Prospective, Non-Interventional Study of Disease Progression and treatment of patients with Polycythemia Vera in the United States Academic Community Clinical Practices. (Does not include secondary PV)
www.clinicaltrials.gov.  NCT02252159

                                                                                                             www.clinicaltrials.gov

                                For further information or questions on these clinical trials please call Evie or Lisa at 225-761-3951 or 225-761-3952.

CLOSED TO ACCRUAL/FOLLOW-UP STATUS

AMGEN Cabs 20130110: Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer Patients-Neulasta. (PI:  Castine)

INCYTE INCB 18424-268: A Randomized Double-Blind, Phase 2 of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic HER2-Negative Breast Cancer.  (PI:  Castine)

LUITPOLD:  IV iron, Injectafer. (PI:  Castine)

NSABP B42:  Post-menopausal women, Femara/Placebo for 5 years posts completion of initial 5 yrs. HT. (PI:  Miletello)

GS-US-370-1296:  mPancreatic Cancer 1st Line, Phase3, randomized, double-blind study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in subjects with previously untreated Metastatic Pancreatic Ducal Adenocarcinoma preceded by a dose-finding lead-in phase. [PI:  Castine]. (Site Initiation:  TBD; Site closed 3/11/2016)

 

Choosing to participate in a clinical trial is an important personal decision. Our physicians and staff are available to assist you in making that decision.

For more information about the clinical trials available you may call the research office at 225-767-0822 ext. 260.